<DOC>
	<DOCNO>NCT00453622</DOCNO>
	<brief_summary>The purpose study identify combine use cardiac troponin enzyme ( cTnT ) brain natriuretic peptide ( BNP ) predict Heart Failure ( HF ) improvement all-cause mortality patient implanted cardiac pacemaker-defibrillation device ( CRT-D ) . Novel biochemical marker identify patient high risk cardiac mortality detect plasma protein analysis also evaluate . Hypothesis # 1 : The combine use cTnT BNP implant predict risk stratify cause mortality HF hospitalization 12 month . Hypothesis # 2 : The change level say biomarkers different point follow-up predict response CRT 12 month . Hypothesis # 3 : The level panel novel inflammatory mediator , namely chemokines , correlate improvement 6-minute walk testing , quality life , leave ventricular ejection fraction CRT patient .</brief_summary>
	<brief_title>RISK Stratification Using Combination Cardiac Troponin T Brain Natriuretic Peptide Patients Receiving CRT-D</brief_title>
	<detailed_description>Primary Endpoint The primary endpoint occurrence either death first HF hospitalization . HF hospitalization must satisfy follow criterion : 1 . Admission hospital &gt; 24 hour least one follow HF worsen symptom : - Increased CHF class - Orthopnea - Paroxysmal nocturnal dyspnea - Edema - Dyspnea exertion , - Gastrointestinal ( GI ) symptoms attributable HF - Placement Status I heart transplant list AND 2 . One follow intensive treatment ( ) HF within 24 hour admission : - Intravenous ( IV ) diuresis - IV inotropic medication prescribe hospitalization , - Increasing frequency dialysis patient chronic renal failure 2.3 Secondary Endpoints Secondary endpoint include : - Cause death - Change NYHA functional class - Number HF related hospitalization - Performance standard 6-minute hall walk test - Quality Life measure Minnesota Living Heart Failure ( MLWHFQ ) questionnaire - Patient global clinical assessment - Left ventricular ejection fraction ( LVEF ) measure echocardiography - LV volume measure echocardiography - LV lead placement position - QRS duration baseline CRT - Number AT/AF , VT/VF episodes - Frequency appropriate/inappropriate ICD therapy - % Atrial Ventricular Pacing - Antiarrhythmic drug utilization - Study relate complication 2.3.1 Response CRT 1 . A positive response CRT define follow : Improvement NYHA functional class least one grade 2 . Improvement echocardiographic LVEF &amp; leave ventricular end diastolic index ( LVEDI ) 3 . Improvement patient global clinical assessment 4 . Improvement 6-minute hall walk 10 %</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>Referred implantation CRTD accord currently accept guideline . 18 year old Ability independently comprehend complete QOL questionnaire Ability provide inform consent study willing able comply prescribe followup Has stable conventional medication least one month prior enrollment Inability successfully implant intravascular lead CRTD device . ( i.e . exclude epicardial lead ) Myocardial infarction unstable angina last 3 week Chronic atrial fibrillation ( continuous AF last &gt; 1 Month ) within 1 year prior enrollment undergone cardioversion AF past month Status 1 classification cardiac transplantation Currently participate clinical trial include active treatment arm Life expectancy le 6 month . Recent ( within 24 hour ) administration Nesiritideâ„¢</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Cardiac Resynchronization Therapy</keyword>
	<keyword>Risk stratification</keyword>
	<keyword>Prediction</keyword>
	<keyword>Proteomics</keyword>
	<keyword>Chemokine</keyword>
	<keyword>cardiac enzyme</keyword>
	<keyword>Brain Natriuretic Peptide</keyword>
</DOC>